Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy
27 août 2024 02h00 HE
|
Memo Therapeutics AG
PRESS RELEASE Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy Seasoned commercial leader with significant international experience Joins ahead of lead development candidate...
Burning Rock Reports Second Quarter 2024 Financial Results
22 août 2024 23h59 HE
|
Burning Rock Biotech Limited
Burning Rock Reports Second Quarter 2024 Financial Results
Autologous Cell Therapy Market Estimated to Grow USD 34.7 Billion by 2027, Rising at a 18.1% CAGR- Transparency Market Research, Inc.
21 août 2024 11h09 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. , Aug. 21, 2024 (GLOBE NEWSWIRE) -- According to Transparency Market Research (TMR), the global autologous cell therapy market...
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
20 août 2024 08h30 HE
|
AIM ImmunoTech Inc.
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Additional commentary published discussing the potential of Ampligen and...
Burning Rock Biotech Limited Announces Expected Delisting of American Depositary Shares
19 août 2024 02h21 HE
|
Burning Rock Biotech Limited
Burning Rock Biotech Limited Announces Expected Delisting of American Depositary Shares
Home Healthcare Market to Reach $760.2 Billion, Globally, by 2033 at 10.5% CAGR: Allied Market Research
16 août 2024 10h11 HE
|
Allied Analytics LLP
Wilmington, Delaware, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Home Healthcare Market by Product and Service (Equipment, Software, and Services),...
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
16 août 2024 07h00 HE
|
AIM ImmunoTech Inc.
– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications – Company to host conference call and webcast today, August...
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
15 août 2024 07h00 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
14 août 2024 16h05 HE
|
Turnstone Biologics Corp.
Turnstone reports second quarter 2024 financial results and provides recent business highlights
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
14 août 2024 16h01 HE
|
Turnstone Biologics Corp.
ORR of 25% and 50% DCR observed in first four evaluable patients treated with TIDAL-01 with advanced CRC